Navigation Links
First individual genome sequence published
Date:9/3/2007

vered 7.5 times, ensuring that each set of contributing chromosomes was covered over 3.2 times for greater than 96% coverage of the two parental genomes. The team at JCVI compared and contrasted the new HuRef diploid genome sequence to earlier versions of published human genomes and found that the HuRef version improved upon both these early versions by providing more and correctly oriented base pairs.

Since the HuRef genome is diploid, each of the parental chromosomes could be directly compared to each other. One of the most surprising and important findings from this research was the high degree of genetic variation that was found between two chromosomes within a single individual.

Each time we peer into the human genome, we uncover more valuable insight into our intricate biology, said Dr. Venter. With this publication, we have shown that human-to-human variation is more than seven-fold greater than earlier estimates, proving that we are in fact very unique individuals at the genetic level. He added, It is clear, however, that we are still at the earliest stages of discovery about ourselves, and only with continued sequencing of more individual genomes will we be able to garner a full understanding of how our genes influence our lives.

Within the human genome, there are different kinds of DNA variants. The most studied type is single nucleotide polymorphisms, or SNPs. These have long been thought to be the most prevalent and perhaps the most important type of variant implicated in human traits and disease susceptibility. However, in this analysis of Dr. Venters genome, the team found a surprising number of other important variants. A total of 4.1 million variants covering 12.3 million base pairs of DNA were uncovered with more than 1.2 million new variants discovered.

Of the 4.1 million variations between chromosome sets, 3.2 million were SNPs, while nearly one million were other kinds of variants, such as insertion/deletio
'/>"/>

Contact: Natalie Bouaravong
press@plos.org
415-568-3445
Public Library of Science
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. A genes first kiss sets off that affair known as puberty
2. Timing is everything: First step in protein building revealed
3. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
6. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Love at first smell
9. Worlds largest rainforest drying experiment completes first phase
10. PCRM develops worlds first cruelty-free insulin assay
11. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Surety Leads Web Symposium to Address Data Integrity Issues in Bio-Sciences Industry 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3